Archives
- 2026-11
- 2026-10
- 2026-09
- 2026-08
- 2026-07
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
RGFP966 and the Celastrol Response in ENKTL
2026-11-22
A 2026 study used RGFP966 as a mechanistic comparator to examine whether HDAC3-associated disruption contributes to celastrol-induced stress and apoptosis in EBV-positive extranodal NK/T-cell lymphoma models. The findings support a partial NCOR2–HDAC3 connection but do not establish direct NCOR2 binding, selective HDAC3 dependence, or clinical efficacy.
SIRT1, Type H Vessels, and Bone Aging
2026-11-21
A study of aged murine bone and senescent cell models links reduced SIRT1 activity to impaired vascular–osteogenic coordination. Its findings support a β-catenin-centered mechanism, while pharmacological specificity, model translation, and clinical relevance remain unresolved.
What RGFP966 Reveals About Celastrol Response
2026-11-20
A study in EBV-positive extranodal NK/T-cell lymphoma models used RGFP966 as a pharmacological comparator to test whether HDAC3-associated perturbation contributes to celastrol responses. The findings support a partial mechanistic link, not a standalone efficacy claim for RGFP966.
How HDAC3 Perturbation Shapes Celastrol Stress
2026-11-20
A study in EBV-positive extranodal NK/T-cell lymphoma models links celastrol-associated apoptosis and lipid stress to disruption of the NCOR2–HDAC3 corepressor axis. RGFP966 served as a pharmacological HDAC3 perturbation tool and partially reproduced selected celastrol-associated changes, supporting pathway involvement without establishing that HDAC3 inhibition alone accounts for the full antitumor response.
SIRT1, Type H Vessels, and Bone Aging
2026-11-19
A murine and cell-based study links SIRT1 activity with vascular–osteogenic coordination, proposing β-catenin signaling and reciprocal paracrine communication as mechanisms. The findings are substantial but remain preclinical, pharmacology-dependent, and limited in their ability to establish clinical relevance or pathway specificity.
HDAC3, Histone Acetylation, and Cholestasis
2026-11-19
Evidence from complementary mouse models, human liver datasets, and liver epithelial cells suggests that HDAC3 is associated with cholestatic injury and that its pharmacological inhibition can restore bile-acid and lipid-homeostasis programs in lithocholic-acid-associated intrahepatic cholestasis. The model-specific failure to protect against mechanical bile-duct obstruction is central to interpreting the mechanism and its translational boundaries.
Measuring Organelle Proximity Beyond Colocalization
2026-11-18
A 2026 workflow shows how super-resolution imaging, computational reconstruction, and pixel-classification segmentation can improve estimates of organelle morphology and spatial proximity. Its strongest evidence concerns measurement performance, not proof that nearby membranes are functionally tethered or that a fluorescent probe alone improves biological outcomes.
When Context Changes What a Result Means
2026-11-18
A chemical identity, a metabolic measurement, and an analytical standard can involve related molecules while supporting very different conclusions. The contrast between sodium acetoacetate and deuterium-labeled degarelix illustrates why research context must accompany every reported result.
Translating mRNA-LNPs Through CMC
2026-11-17
A paper-centred interpretation of how lipid chemistry, carrier selection, manufacturing strategy, analytical characterization, stability assessment, and comparability planning shape the translation of mRNA lipid nanoparticle systems.
SIRT1, Type H Vessels, and Bone Repair
2026-11-17
A literature-focused analysis of a mouse and cell study linking age-related SIRT1 decline to vascular–osteogenic dysfunction, with emphasis on the β-catenin mechanism, evidence layers, and limits on translation.
SRT1720 and the Bone–Vessel Aging Axis
2026-11-16
Evidence from aged mice and senescent bone and endothelial cell models links pharmacological SIRT1 activation with improved vascular–osteogenic coordination, while leaving important questions about pathway specificity, mechanical benefit, safety, and human applicability.
Context Is the Result: SIRT1 in Bone Repair
2026-11-16
A study of pharmacological SIRT1 activation links age-associated vascular and osteogenic decline to β-catenin signaling, but the meaning of its positive findings changes substantially between cell assays, murine tissue models, and clinically relevant outcomes.
SIRT1, Type H Vessels, and Bone Repair
2026-11-15
Published mouse and cell-model evidence links SIRT1 activation with improved vascular–osteogenic coordination in aging bone. The findings support a β-catenin-centered mechanism, but pharmacological specificity, causal direction, durability, and relevance to human osteoporosis remain unresolved.
SIRT1, Type H Vessels, and Bone Repair
2026-11-14
A literature-focused analysis of how the cited study links reduced SIRT1 signaling with vascular and osteogenic aging, and how pharmacological activation was associated with improved bone structure and defect repair in preclinical models.
SIRT1, Type H Vessels, and Bone Repair
2026-11-13
A paper-centred interpretation of a multilevel preclinical study linking age-associated SIRT1 decline with vascular senescence, impaired osteogenic activity, and defective skeletal regeneration through β-catenin/Wnt-associated vascular–osteogenic communication.